W. Charles Huskins, MD, MSc, FSHEA, FIDSA, FPIDS
Dr. Huskins is a Professor of Pediatrics in Mayo Clinic College of Medicine, the Chair of Pediatric Infectious Diseases in the Department of Pediatric and Adolescent Medicine at Mayo Clinic, and the Healthcare Epidemiologist and Vice Chair of Quality for the Mayo Clinic Children’s Center.
He is the IDWeek 2015 SHEA Co-Chair. His other SHEA activities include serving as the Scientific Chair of the 2011 SHEA annual meeting and a member of the SHEA Annual Meeting planning committee from 2008-11, a member of the SHEA Education Committee since 2012, and the SHEA liaison to the CDC’s Emerging Infections Program Healthcare Associated Infections/Community Interface Steering Group. Dr. Huskins is also a member of the CDC’s Healthcare Infection Control Practices Advisory Committee (HICPAC).
Dr. Huskins brings his healthcare epidemiology expertise to quality improvement efforts both in his role in quality leadership at Mayo Clinic and at the Children’s Hospital Association (CHA). He is currently serving as a member of the CHA Board of Trustee’s Clinical Quality Improvement Subcommittee and as a leader on several of CHA’s improvement collaboratives (CLABSI, sepsis).
Dr. Huskins has used his epidemiologic training and expertise to play an integral role in the Mayo Center for Clinical and Translational Science initially as a leader of the post-doctoral education and mentor training programs and now as a leader of child health research efforts. He has worked with child health research leaders at other centers with NIH Clinical and Translational Science Awards to advance child health research nationally.
Dr. Huskins’ research interests include the prevention of CLABSI, performance characteristics of markers of sepsis and optimizing empiric antibiotic therapy in critically ill children, preventing spread of influenza in schools through behavioral and environmental interventions, and clinical/translational research study design, methodology, implementation, and evaluation, and infection control in resource-limited settings. He is currently leading a multicenter clinical trial of short-course therapy for community acquired pneumonia in children being conducted through the Antimicrobial Research Leadership Group with support from the National Institute of Allergy and Infectious Diseases. The study is using a novel study design for antimicrobial stewardship research. He was also the lead investigator of the NIAID-supported Strategies to Reduce Transmission of Antimicrobial Resistant Bacteria in Intensive Care Units (STAR-ICU) study, a multicenter clinical trial of interventions to prevent spread of methicillin-resistant Staph. aureus and vancomycin-resistant enterococcus.